In addition to the above SGLT2 inhibitors approved by the FDA and EMA for cardiovascular indications, another SGLT2 inhibitor, sotaliflozin, also present benefits for cardiovascular death and heart failure. This evidence concerns the gene SLC5A2 and heart failure.